Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

FRM predicts compelling case for active management

Tuesday, January 08, 2013
Opalesque Industry Update - FRM, Man Group's $19.5bn fund of funds and managed account business has published its 'early view' on hedge funds.

Market outlook

  • Fiscal reformation across developed markets will continue to be a dominant factor on market price action through 2013 and beyond.
  • In the US, the next milestones will be the final decisions on spending cuts and the debt ceiling deadline, both of which fall on 1 March 2013.
  • In Europe, politics is likely to provide the potential stumbling-blocks. The Italian elections in February are the first test, and afterwards it difficult to see how any concrete decisions related to the fiscal compact might be agreed before the German election takes place in September.
  • Emerging markets in aggregate appear to be relatively stable with modest growth expectations over the coming period.

Hedge fund outlook

  • The outlook for traditional investments is uncertain: risk-free assets have negative real yields and the likelihood of an increase in short-term rates appear to be slim to none.
  • With the outlook for passive investing so poor, the case for active management is even more compelling. As a result, investors are continuing to allocate to active management in order to achieve the desired outcomes from their portfolios, as evidenced by the growth of the hedge fund industry in 2012 and expectations of further growth in 2013.
  • It is our long-term expectation that this delivery of absolute returns will continue to be at the core of hedge fund investing.

Press release

bc

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for